Key Takeaways
- Revenue surged 64% YoY on strong order convergence in Latin markets, while nine-month margins dipped to 14.6% as the company absorbed costs from a rapid new-product push.
- New products are the margin story: Portfolio expansion is compressing blended gross margins now, but management expects cost efficiencies to kick in over 6–18 months as supply chains are streamlined.
- Injectables demand is accelerating on larger orders from existing markets and entry into new geographies, while the oral solid segment faces stiff competition and pricing pressure that may take two to three quarters to normalize.
- The HAL joint venture is on track for an October 2024 start, with major equipment ordered and construction beginning this month; the Prague packaging line, delayed by the Red Sea embargo, now opens in late March.
- What to watch next quarter: Whether other expenses normalize as guided, the pace of Dehradun facility approvals from Latin inspections, and any concrete disclosure on new geography entries.
Revenue Growth & Geographic Expansion
- Latin America drove the quarter: Better order convergence in the Latin market powered the 64% YoY revenue jump, and management expects Latin to grow faster than other geographies going forward.
- Five new Central American countries entered over the nine-month period: Guatemala, El Salvador, Honduras, Nicaragua, and the Dominican Republic, plus Ecuador in Latin America.
- Francophone Africa entry is imminent: Agents and distributors have been scouted, agreements are in process, and the launch is set for April 2024, the first quarter of FY25, with products already selected by the regulatory team.
- Further geography expansion is planned over the next two to three years, including additional Latin American countries, Francophone countries, and some East African countries; management will disclose details as they become concrete.
- The export-domestic mix target is 75-25, with focus always on exports, where profit is higher than in the domestic business.
Margin Dynamics & New Product Impact
- Nine-month EBITDA margin declined to 14.6% from 15.4% a year ago, driven by lower margin realizations in some products, while Q3 standalone margin improved 298 bps YoY on better sales realizations.
- Rapid portfolio expansion is compressing margins: The company has added many new products over the past three quarters, and new products carry lower initial cost efficiencies; as supply chains are streamlined, margins improve, a process that can take six to 18 months depending on the product and volumes.
- The margin drag is not an injectable-vs-oral mix issue: Management clarified that contraction comes from the pace of new product additions, not from segment mix, and that every quarter should not impact books heavily unless a product represents a big chunk of revenue.
- Other expenses spiked due to new product development costs, new JV setup expenses, and some commissions booked on late-realized payments; these are expected to normalize by next quarter.
Srivardhan: "When we add new products, the cost efficiencies of those products are not there. The more we streamline the supply chain of those new products, we are able to get a better margin out of those products. Since we are adding new products rapidly, the margin seems to be declining."
Segment Trends: Injectables vs. Oral Solids
- Injectables demand is rising on three fronts: increased demand from newer geographies, larger order sizes from existing customers and markets, and the company's long history and clean track record in the segment.
- Oral solids face stiff headwinds: The tablet and nutraceutical business declined due to intense competition, pricing pressure, and a wave of new factories that opened in the past two years when COVID relaxed regulations and registration guidelines.
- Oral normalization is expected after two to three quarters, though the revenue share ratio currently appears tilted; management expects rapid injectables growth to continue alongside this recovery.
Srivardhan: "we are facing a lot of stiff competition in the market that we are present in. And there is a lot of pricing pressure as well. We see that there have been a lot of new factories that have opened up in the past two years when the COVID had relaxed the regulations and registration guidelines."
Facility Upgrades & Regulatory Approvals
- Dehradun tablet facility is under upgradation with a Latin country inspection scheduled for end of March and the first week of April; once that approval is secured, it automatically triggers approvals in three to four other Latin countries, and by year-end 2024 may trigger an East European country approval.
- The Prague packaging line was delayed by the Red Sea embargo, which held up equipment shipments and prevented personnel travel; it is now opening on 25th or 26th of March, and its first-quarter revenue will be accounted in Q1 FY25.
- Prague is a margin play: The facility is positioned to access better-developed European and American markets, where Indian manufacturing expertise creates cost efficiencies and selling prices support higher margins.
- Manufacturing upgrades are underway across plants to secure regulatory approvals from better countries, ROW, and semi-regulated markets, expanding the addressable market.
Ashwani Khemka: "But due to this Red Sea embargo and the delays in shipments to the equipment's to Prague, the things got delayed and people could not travel."
HAL Joint Venture & Management Expansion
- The HAL JV is on schedule: Nearly 70% of major equipment has been ordered, remaining SLA equipment is under negotiation, the plant layout is in process, and ₹2.5 crores has been invested so far; construction is starting this month, with machines expected to arrive in India in June and July.
- Revenue from HAL is expected to begin in Q4, and the JV is committed to start operations in October 2024, possibly 15–20 days ahead of that deadline.
- Management team is scaling up: An HR company has been hired to scout talent domestically and internationally; one or two new senior people are joining every month, and the board is set to expand with very senior, renowned industry figures.
Ashwani Khemka: "as committed that we are going to start in the month of October 2024, it will be strictly on that deadline and maybe 15-20 days before that also."
Pushback & Unanswered Questions
- Segment-level margins were requested but declined: Management said it would be difficult to disclose margins across the three reported segments now and would revisit the question in two or three quarters.
- Other expense split for JV front-ending costs was asked but not provided; management said they would need to come back with those numbers.
- Market share data for export and domestic was requested along with a two-to-three-year plan; management said it is difficult to comment on market share specific to a region, as it depends on the market and product.
- Aspirational revenue numbers for FY27 and FY28 were not given; management stated only that the company is growing exponentially and closed at a good number as previously guided, with details to be shared when processes become operational.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Other expense normalization | Expenses from new product development, JV setup, and late commissions to come down | Next quarter (Q4 FY24) |
| Oral solid segment normalization | Recovery from current competition and pricing pressure | Two to three quarters |
| Francophone Africa entry | Launch with agents, distributors, and selected products | April 2024 (Q1 FY25) |
| Prague packaging line operational | Delayed by Red Sea embargo; now opening late March | 25th or 26th of March 2024 |
| Dehradun Latin country inspection | Facility upgradation and regulatory inspection | End of March / first week of April 2024 |
| Dehradun cascade approvals | Automatic approval in 3–4 Latin countries after first approval; East European country trigger | Latin: post-inspection; East Europe: year-end 2024 |
| HAL JV start of operations | Construction starting, machines arriving June–July | October 2024, possibly 15–20 days earlier |
| HAL revenue commencement | First revenue from the JV | Q4 FY24 |
| Segment margin disclosure | Management to revisit disclosing margins across three segments | Two to three quarters |
Key Metrics
| Metric | Q3 FY24 |
|---|---|
| Revenue | ₹14.96 cr, +64% YoY |
| EBITDA margin | 13.1%, +298 bps YoY from 10.1% |
| Net profit | ₹1.65 cr, +73% YoY |
| PAT margin | 11%, +59 bps YoY from 10.4% |
| 9M FY24 revenue | ₹41.55 cr, +52% YoY |
| 9M FY24 EBITDA | ₹6.08 cr, +44% YoY |
| 9M FY24 EBITDA margin | 14.6%, -80 bps YoY from 15.4% |
| 9M FY24 PAT margin | 11.8%, -100 bps YoY from 12.8% |
| Injectables revenue growth | +89% YoY |
| Nutraceuticals revenue growth | +27% YoY |
| Revenue mix | 35.2% domestic, 64.8% exports |
| CMO sales | ~11% of revenue |
| Capacity utilization, injectables | 70% |
| Capacity utilization, orals | 35% |
| HAL JV total capex | ₹35–38 cr, ~10% invested so far |
| Total capex across all projects | ~₹31 cr, ₹5 cr already invested |